- Home
- UTHR
as 07-26-2024 4:00pm EST
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Upcoming Earnings Alert:
Get ready for potential market movements as United Therapeutics Corporation UTHR prepares to release earnings report on 31 Jul 2024.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 12.1B | IPO Year: | 1999 |
| Target Price: | $327.58 | AVG Volume (30 days): | 446.8K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 21.12 | EPS Growth: | 42.41 |
| 52 Week Low/High: | $208.62 - $343.98 | Next Earning Date: | 07-31-2024 |
| Revenue: | $2,498,300,000 | Revenue Growth: | 26.09% |
| Revenue Growth (this year): | 20.09% | Revenue Growth (next year): | 8.16% |
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 17 '24 | Sell | $334.75 | 309 | $103,436.54 | 130 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 17 '24 | Sell | $333.52 | 472 | $157,422.57 | 439 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 17 '24 | Sell | $332.59 | 795 | $264,409.92 | 911 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 17 '24 | Sell | $331.60 | 782 | $259,308.38 | 1,706 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 17 '24 | Sell | $330.17 | 997 | $329,177.50 | 2,488 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 17 '24 | Sell | $329.32 | 245 | $80,683.52 | 3,485 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 17 '24 | Sell | $337.34 | 149 | $50,264.02 | 130 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 17 '24 | Sell | $335.36 | 485 | $162,651.59 | 279 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 17 '24 | Sell | $334.53 | 883 | $295,386.46 | 764 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 17 '24 | Sell | $333.50 | 1,051 | $350,506.82 | 1,647 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 17 '24 | Sell | $332.67 | 810 | $269,466.59 | 2,698 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 17 '24 | Sell | $331.50 | 54 | $17,901.26 | 3,508 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 17 '24 | Sell | $328.10 | 168 | $55,120.88 | 3,562 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 11 '24 | Sell | $329.79 | 105 | $34,628.37 | 130 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 11 '24 | Sell | $328.47 | 213 | $69,964.56 | 235 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 11 '24 | Sell | $327.91 | 148 | $48,530.30 | 448 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 11 '24 | Sell | $326.41 | 501 | $163,533.31 | 596 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 11 '24 | Sell | $325.18 | 694 | $225,671.73 | 1,097 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 11 '24 | Sell | $324.26 | 1,248 | $404,680.35 | 1,791 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 11 '24 | Sell | $323.02 | 507 | $163,770.02 | 3,039 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 11 '24 | Sell | $321.18 | 184 | $59,096.62 | 3,546 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 11 '24 | Sell | $328.73 | 141 | $46,350.59 | 130 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 11 '24 | Sell | $327.59 | 454 | $148,725.22 | 271 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 11 '24 | Sell | $326.60 | 1,159 | $378,525.69 | 725 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jul 11 '24 | Sell | $325.57 | 990 | $322,310.44 | 1,884 | SEC Form 4 |
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
Zacks
10 hours ago
Implied Volatility Surging for United Therapeutics (UTHR) Stock Options
MT Newswires
a day ago
HC Wainwright Adjusts Price Target on United Therapeutics to $400 From $300, Maintains Buy Rating
Zacks
a day ago
Will PTC Therapeutics (PTCT) Report Negative Q2 Earnings? What You Should Know
Business Wire
3 days ago
United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024
Simply Wall St.
4 days ago
Is Now The Time To Put United Therapeutics (NASDAQ:UTHR) On Your Watchlist?
Associated Press Finance
6 days ago
Meet some of the world's cleanest pigs, raised to grow kidneys and hearts for humans
Zacks
7 days ago
If You Invested $1000 in United Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
MT Newswires
9 days ago
United Therapeutics Insider Sold Shares Worth $2,355,544, According to a Recent SEC Filing
Compare UTHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.